<DOC>
	<DOCNO>NCT00503126</DOCNO>
	<brief_summary>Pharmacokinetics safety weight base bivalirudin child</brief_summary>
	<brief_title>Bivalirudin Procedural Anticoagulant Pediatrics</brief_title>
	<detailed_description />
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Male nonpregnant female , age range birth 16 year age . Expected undergo percutaneous intravascular procedure management congenital heart disease . Written inform consent legal guardian/parent . Life expectancy least 15 day study entry . Assent patient old 8 year , whenever possible . History intracerebral bleed ( neonate confirm ultrasound head scan prior procedure ) , cerebral arteriovenous malformation prior bleed neurological deficit . Gastrointestinal genitourinary bleeding within last 2 week exclude normal menstrual cycle . Cerebrovascular accident within 6 month , cerebrovascular accident residual neurological deficit . Known congenital acquire bleed clot disorder . Patients undergoing renal dialysis . * Weight &lt; 2.5 kg . Confirmed pregnancy time enrollment breast feeding ( female childbearing potential ) . Known allergy bivalirudin hirudinderived drug , know sensitivity component bivalirudin ( Angiomax® ) . Any condition investigator 's opinion would constitute contraindication participation study , cause inability comply study requirement . Participation another investigational therapeutic drug therapeutic device trial within 30 day start study . Patients receive warfarin ( Coumadin® ) therapy whose INR &gt; 1.5 . Patients discontinue UFH least 30 minute prior study drug bolus . Patients receive dose LMWH within 8 hour prior study drug bolus . Patients previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>pediatrics</keyword>
	<keyword>bivalirudin</keyword>
</DOC>